Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/projects/825-a-phase-ii-multicentre-open-label-study-of-cabozantinib-as-2nd-line-treatment-in-subjects-with-unresectable-locally-advanced-or-metastatic-renal-cell-carcinoma-with-a-clear-cell-component-who-progressed-after-1st-line-treatment-with-checkpoint-inhibitors